Die mikroverkapselte Monatsdepotform von Leuprorelin: Tierversuche und interne Struktur der Mikrokapseln

  • Y. Ogawa
Conference paper

Zusammenfassung

1974 gelang Fujino et al. die Synthese von Leuprorelinacetat, welches zum damaligen Zeitpunkt das potenteste entdeckte LHRH-Analogon war (Abb. 1). Es ist zur Stimulierung der Gonadotropin-Ausschüttung mehr als 100mal so aktiv wie das native LHRH. Die Wirksamkeit des Leuprorelin zur Behandlung des Prostatakarzinoms konnte in mehreren Studien bestätigt werden (Santen et al. 1984; Wojciechowski et al. 1986). 1985 wurden von der FDA in den USA eine wäßrige Lösung dieses Medikaments (Lupron) für die Therapie des Prostatakarzinoms als tägliche Injektion in einer Dosis von 1 mg genehmigt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Fujino M, Fukuda T, Shinagawa S, Kobayashi S, Yamazaki I, Nakayama R, Seely JH, White WF, Rippel RH (1974) Synthetic analogs of luteinizing hormone releasing hormone (LH-RH) subsituted in position 6 and 10. Biochem Biophys Res Commun 60: 406–413PubMedCrossRefGoogle Scholar
  2. Ogawa Y, Okada H, Yamamoto M, Shimamoto T (1988a) In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem Pharm Bull (Tokyo) 36: 2576–2581CrossRefGoogle Scholar
  3. Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T (1988b) A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or coply(lactic/glycolic) acid. Chem Pharm Bull (Tokyo) 36: 1096–1103Google Scholar
  4. Ogawa Y, Yamamoto M, Takada S, Okada H, Shimamoto T (1988c) Controlled release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: Influence of molecular weight and copolymer ratio of polymer. Chem Pharm Bull (Tokyo) 36: 1502–1507Google Scholar
  5. Ogawa Y, Okada H, Heya T, Shimamoto T (1989) Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: Serum drug level and pharmacological effects in animals. J Pharm Pharmacol 41: 439–444Google Scholar
  6. Okada H, Heya T, Ogawa T, Toguchi H, Shimamoto T (1991) Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate. Pharm Res 8: 584–587PubMedCrossRefGoogle Scholar
  7. Santen RJ, Demers LM, Max DT, Smith J, Stein BS, Glode LM (1984) Long-term effects of administration of a gonadotropin-releasing hormone super agonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab 58: 397–400PubMedCrossRefGoogle Scholar
  8. Tice TR, Cowsar DR (1984) Biodegradabel controlled-release parenteral systems. Pharm Tech 26: 26–36Google Scholar
  9. Wojciechowski NJ, Carter CA, Skoutakis VA, Bess DT, Falbe WJ, Mickle TR (1986) Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm 20: 746–751PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Y. Ogawa

There are no affiliations available

Personalised recommendations